Achieve Life Sciences (ACHV) Expected to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $10.65 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). On average, analysts expect Achieve Life Sciences to post ($0.92) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

Achieve Life Sciences Stock Performance

NASDAQ:ACHV opened at $6.85 on Thursday. Achieve Life Sciences has a twelve month low of $2.62 and a twelve month high of $8.64. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87. The company has a 50-day moving average of $7.50 and a 200-day moving average of $5.64. The firm has a market cap of $704.88 million, a price-to-earnings ratio of -4.42 and a beta of 2.30.

Insiders Place Their Bets

In related news, Director Richard Stewart sold 20,626 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director directly owned 208,249 shares of the company’s stock, valued at approximately $1,768,034.01. The trade was a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ACHV shares. UBS Group restated a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Morgan Stanley initiated coverage on Achieve Life Sciences in a research report on Thursday, August 13th. They set an “overweight” rating and a $13.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 19th. HC Wainwright reissued a “buy” rating on shares of Achieve Life Sciences in a research note on Friday, October 23rd. Finally, Wall Street Zen cut Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.50.

About Achieve Life Sciences

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.